 acelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) reported a net loss of $9.7 million or $0.21 basic and diluted net loss per share for the fourth quarter of 2016 and a net loss of $43.2 million or $0.95 basic and diluted net loss per share for the full year ended, December 31, 2016.    
 the most important milestone in the fourth quarter was the submission of a new drug application or NDA with the U.S. Food and Drug Administration for a 30 microgram sublingual sufentanil tablet for the the treatment of adult patients experiencing moderate to severe acute pain in a medically supervised setting.    
 recently this application was accepted for filing and a PDUFA date of October 12, 2017 was assigned.    
 we continue to be excited about the potential for this product because of its simple single-dose applicator design. and is administered to the patient by health care professionals.    
 we refined our expectations for the market potential in the U.S. as well as in Europe where the product is called ARX004. and we estimate peak revenues to be $1.1 billion